Market Introduction
South and Central America includes Brazil, Argentina, and Rest of South and Central America. The market for the protein binding assay in the region is expected to increase in developments in the pharmaceutical and biotechnological industries, and rising healthcare expenditure. Also, rise in the availability of numerous advanced technologies utilized for protein binding is expected to increase adoption of protein binding assay in the region. Brazil is the fifth largest country in the world, both by area and by population. The rising spending in the healthcare sector and the pharmaceutical and medical device firms, and rising demand for clinical trials are driving the growth of the protein binding assay market in Brazil. Brazil is among one of the two South American countries that has its own contract research organization (CROs) association. The CROs and sponsors that wishes to start a clinical trial requires approval from local ethics committees near the investigator sites in the initial stages as well as later from the Conselho Nacional de Saude, the national ethics committee. According to ABRACRO, a CRO association in Brazil stated that even after having over 300,000 active physicians and approximately 400 ethics committees for clinical research, Brazil is still running slow in comparison to other countries such as Chile and Argentina. This attributes to the slow regulatory process prior to trial conduction initiation. However, the developing healthcare infrastructure leading to increasing number of new drug applications from Brazil as well as adoption of protein binding assays in drug discovery & development is expected to drive the growth of Brazil protein binding assay market over the forecast years.
The COVID-19 pandemic has severely affected medical services in South and Central America. The countries in this region are among popular tourist destinations. They are also famous for medical tourism. According to Worldometer, as of July 29, 2021, Brazil has recorded 19,797,516 new cases, including 553,272 fatalities. Countries are likely to extend the lockdown period, which is eventually hampering the healthcare sector in the region. Market players and end users are facing losses in their business due to temporary discontinuation of enterprises. Outsourcing for clinical trials very local in Latin America. Latin America has always been known for its legal and regulatory knowledge, its language skills, and its compatible time zone with America. Latin America is not caught up with inflation regarding total cost, and so promotes a very strong value proposition of having the ability to provide cost-effective services. When it comes to Spanish and Portuguese language skills, Latin America is probably the only region in the world that offers the combination of language skills at scale plus cost savings. This works in favor of US markets due to the huge Spanish population present in the US. Global companies are gaining several regional and business opportunities, especially in large countries like Brazil and Argentina where the domestic market is also large (nearly 60-70%). With established regional markets and promises of lower costs, Latin America is considering to be the fastest growing destination for offshore services in the healthcare industry.
Market Overview and Dynamics
The protein binding assay market in SCAM is expected to grow from US$ 17.92 million in 2021 to US$ 34.42 million by 2028; it is estimated to grow at a CAGR of 9.8% from 2021 to 2028. Growing Rising CRO industry in emerging markets; contract research organizations (CROs) have rapidly emerged as a force in drug development and clinical trial recruiting. emerging countries are emerging as attractive outsourcing locations for drug manufacturers. Low manufacturing and operating costs are driving the growth of the CRO industry. Recent growth in the pharmaceutical industry indicates a positive outlook for protein binding assay market. The CRO industry is experiencing strong growth owing to surging technological innovations, changing regulations, and increasing outsourcing levels. There is a continuous growth in scientific base and capabilities owing to the growing contribution of clinical research, centralized healthcare institutions, well-qualified and highly motivated investigators, and excellent clinical trial facilities.
Key Market Segments
Based on technology is segmented into ultracentrifugation ultrafiltration, equilibrium dialysis, surface plasmon and others. In 2020, the equilibrium dialysis segment is likely to hold the largest share of the market, by technology. Based on the end user was segmented into contract research organization, pharmaceutical & biotechnology companies, and research & diagnostic laboratories. In 2020, the pharmaceutical & biotechnology companies segment is likely to hold the largest share of the market, by end user.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the protein binding assay market in SCAM are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Biotium, Inc, Eurofins Scientific, General Electric Company, MERCK KGaA, MicroConstants, Inc, Ltd, Sartorius AG, SOVICELL GMBH, and THERMO FISHER SCIENTIFIC INC. among others.
Reasons to buy report
SCAM PROTEIN BINDING ASSAY MARKET SEGMENTATION
By Technology
By End User
By Country
Company Profiles